Summary
Michael was appointed as a Senior Clinical Lecturer in Respiratory Medicine in 2016 and currently works in the Respiratory Research Group within the Institute of Clinical and Applied Health Research.
Michael undertook his undergraduate training in Dundee before moving to Edinburgh where he completed his Foundation Training. He moved to Hull in 2009 as an NIHR Academic Clinical Fellow before completing his MD investigating the role of platelets and the endothelium in idiopathic pulmonary fibrosis in 2013. He was subsequently awarded an NIHR Clinical Lecturer position at Hull York Medical School where he continued his interstitial lung disease research and developed his interest in COPD and the use of technology in healthcare.
He is an honorary consultant in Hull and East Yorkshire Hospitals NHS Trust. His sub-speciality interests include interstitial lung disease and COPD for which he undertakes weekly clinics. He leads the Hull and East Yorkshire Hospitals COPD service.
Journal Article
Tele-rehabilitation for patients who have been hospitalised with Covid-19: a mixed-methods feasibility trial protocol
Hyde, L., Simpson, A. J., Nettleton, M., Shepherdson, J., Killingback, C., Marshall, P., …Green, A. (2022). Tele-rehabilitation for patients who have been hospitalised with Covid-19: a mixed-methods feasibility trial protocol. Physical Therapy Reviews, https://doi.org/10.1080/10833196.2022.2028963
Domiciliary Cough Monitoring for the Prediction of COPD Exacerbations
Crooks, M. G., den Brinker, A. C., Thackray-Nocera, S., van Dinther, R., Wright, C. E., & Morice, A. H. (2021). Domiciliary Cough Monitoring for the Prediction of COPD Exacerbations. Lung, 199(2), 131-137. https://doi.org/10.1007/s00408-021-00435-9
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial
Monk, P. D., Marsden, R. J., Tear, V. J., Brookes, J., Batten, T. N., Mankowski, M., …Rodrigues, P. M. (2021). Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. The lancet. Respiratory medicine, 9(2), 196-206. https://doi.org/10.1016/S2213-2600%2820%2930511-7
Azithromycin for sarcoidosis cough: an open label exploratory clinical trial
Fraser, S. D., Thackray-Nocera, S., Shepherd, M., Flockton, R., Wright, C., Sheedy, W., …Hart, S. P. (2020). Azithromycin for sarcoidosis cough: an open label exploratory clinical trial. ERJ Open Research, 6(4), Article 00534. https://doi.org/10.1183/23120541.00534-2020